Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07JZT
|
|||
| Former ID |
DIB005324
|
|||
| Drug Name |
LA-EP2006
|
|||
| Indication | Neutropenia [ICD-11: 4B00.0; ICD-9: 288] | Phase 3 | [1] | |
| Company |
Sandoz
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor (CSF3) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Malaria | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| WikiPathways | Cytokines and Inflammatory Response | |||
| Hematopoietic Stem Cell Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01516736) Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 724518). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.